ArticlePloS one2026
Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze the prognostic factors influencing outcomes in hepatocellular carcinoma (HCC) patients initially treated with atezolizumab-bevacizumab (Ate-Bev).
methodsWe conducted a retrospective study on 47 treatment-naïve HCC patients (40 men; median age, 56 years) who were treated with Ate-Bev between September 2020 and July 2022 and underwent at least one response assessment based on the Response Evaluation Criteria in Solid Tumors 1.1. We evaluated the clinical variables and imaging features of pre-treatment magnetic resonance imaging (MRI). Using multivariable Cox hazard regression analysis, we analyzed prognostic factors for progression-free survival (PFS).
resultsDuring the follow-up period (range, 1.5-24.9 months), 33 patients (70.2%) experienced tumor progression. The median PFS was 4.3 months (95% confidence interval [CI], 2.8-8.5 months). Nine patients received concomitant radiotherapy. Multivariable analysis indicated that younger age (hazard ratio [HR], 0.95; 95% CI, 0.92-0.99; P = 0.013), absence of concomitant radiation therapy (HR, 0.22; 95% CI, 0.07-0.69; P = 0.009), tumor extent ≥10 cm (HR, 2.54; 95% CI, 1.17-5.55; P = 0.019), and peritumoral arterial-phase hyperenhancement on the MRI (HR, 2.15; 95% CI, 1.00-4.63; P = 0.049) were factors associated with poor PFS.
conclusionsAge, concomitant radiation therapy, tumor extent, and peritumoral arterial-phase hyperenhancement on MRI were associated with PFS in patients with HCC who were initially treated with Ate-Bev.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.